The winter of chinese VC industry may end in next year
Posted by tracy ma on Friday, November 25, 2011
Under: pharmaceutical raw materials
At present, the international price of vitamin C has dropped to $ 3 / kg, and in 2009 two years ago, vitamin C can also sell $ 12 / kg high, and now the price has shrunk 75%, vitamin C price fell to the bottom . The price of vitamin C in this Waterloo, the hardest hit when the number of Chinese vitamin raw material drug companies.
According to statistics, at present, global production of Vitamin C in about 90% concentrated in China. In 2010, total global demand for vitamin C is 12 million tons, but China's "contribution" out of vitamin C has reached 200,000 tons, chia seed almost double than the total global demand, of which nearly half of the production comes from known domestic Vitamin C "five families" of Northeast Pharmaceutical, North China Pharmaceutical, Shijiazhuang Pharmaceutical Group, Jiangshan Pharmaceutical and Rubi pharmaceutical. In fact, the vitamin industry in China for four years before the days are very much, and even once had $ 12 / kg of "scenery." High prices of vitamins, vitamins from the people continue to increase demand for the product, medicine, food, feed, cosmetic and other industries are vitamin API downstream industry, which makes 2008 to 2009, the annual demand for vitamin C 5% increase annually.
Decline began in the second half of 2009. Because vitamin C, large profit margins, from small pharmaceutical raw materials companies want a slice, Ma C production have on the project, over-investment, leading to excess production of Vitamin C production. According to statistics, in 2009 alone, there are many companies begin production vitamin C, and even has been to produce home-based production of penicillin began to vitamin C converting. China's growing army of vitamin C production, and finally lead to excess production of Vitamin C production situation. The end of 2009, the National Development and Reform Commission told the China-dimensional C overcapacity issued a warning, but failed to lead to benefits or reduce pharmaceutical companies enough attention.
If the resulting price plunge vitamin C is the culprit of excess production capacity and output, then the confusion of vitamin industry trade management is one of the promoter. It is understood that China's pharmaceutical enterprises If you want to project on Ma C, need to declare the local authorities. Companies to get approval, if the declaration is based on API shall be in accordance with the "Drug Administration Law" stipulates that relevant departments of the State only after drug approval number of production, if not get the drug approval number, companies will think of some alternative approach "Quxianjiuguo", such as the project as a feed additive or food additives to declare, respectively, by the Ministry of Agriculture and AQSIQ issued relevant documents. This allows you to bypass strict state control of drug approval number, resveratrol to apply for the feed or food additive status symbol to get the production. According to the State Food and Drug Administration Web site show that China now has Vitamin C production approval number of pharmaceutical companies over 2000, more difficult to control, at the same time, a vitamin industry is a lack of development of the industry standard specification documents, eventually led to the production control, production of excess vitamin C industry from the initial "win-win" to winter.
In fact, in addition to the hardest hit of vitamin C, vitamin API currently market as a whole has shown a decline. According to the analysis poor sales in addition to vitamin excess capacity, the global market for vitamin demand continues to shrink the important factors. On the one hand, weak demand in overseas markets, overseas buyers are no longer as before, a large number of Yahuo, but decided to purchase according to the amount of volume. On the other hand, China's domestic vitamin market in pork, eggs and other agricultural products in the context of falling prices, farmers invest in a drop in demand, resulting in decline in the amount of feed-grade vitamin. At present, China's vitamin bulk raw material drug companies are trying to spend the winter, in addition to their own transformation, as the "five families" such as vitamin advantage of national pharmaceutical companies are all looking forward to the development of industry standards promulgated normative documents. Source:http://www.cospcn.com
According to statistics, at present, global production of Vitamin C in about 90% concentrated in China. In 2010, total global demand for vitamin C is 12 million tons, but China's "contribution" out of vitamin C has reached 200,000 tons, chia seed almost double than the total global demand, of which nearly half of the production comes from known domestic Vitamin C "five families" of Northeast Pharmaceutical, North China Pharmaceutical, Shijiazhuang Pharmaceutical Group, Jiangshan Pharmaceutical and Rubi pharmaceutical. In fact, the vitamin industry in China for four years before the days are very much, and even once had $ 12 / kg of "scenery." High prices of vitamins, vitamins from the people continue to increase demand for the product, medicine, food, feed, cosmetic and other industries are vitamin API downstream industry, which makes 2008 to 2009, the annual demand for vitamin C 5% increase annually.
Decline began in the second half of 2009. Because vitamin C, large profit margins, from small pharmaceutical raw materials companies want a slice, Ma C production have on the project, over-investment, leading to excess production of Vitamin C production. According to statistics, in 2009 alone, there are many companies begin production vitamin C, and even has been to produce home-based production of penicillin began to vitamin C converting. China's growing army of vitamin C production, and finally lead to excess production of Vitamin C production situation. The end of 2009, the National Development and Reform Commission told the China-dimensional C overcapacity issued a warning, but failed to lead to benefits or reduce pharmaceutical companies enough attention.
If the resulting price plunge vitamin C is the culprit of excess production capacity and output, then the confusion of vitamin industry trade management is one of the promoter. It is understood that China's pharmaceutical enterprises If you want to project on Ma C, need to declare the local authorities. Companies to get approval, if the declaration is based on API shall be in accordance with the "Drug Administration Law" stipulates that relevant departments of the State only after drug approval number of production, if not get the drug approval number, companies will think of some alternative approach "Quxianjiuguo", such as the project as a feed additive or food additives to declare, respectively, by the Ministry of Agriculture and AQSIQ issued relevant documents. This allows you to bypass strict state control of drug approval number, resveratrol to apply for the feed or food additive status symbol to get the production. According to the State Food and Drug Administration Web site show that China now has Vitamin C production approval number of pharmaceutical companies over 2000, more difficult to control, at the same time, a vitamin industry is a lack of development of the industry standard specification documents, eventually led to the production control, production of excess vitamin C industry from the initial "win-win" to winter.
In fact, in addition to the hardest hit of vitamin C, vitamin API currently market as a whole has shown a decline. According to the analysis poor sales in addition to vitamin excess capacity, the global market for vitamin demand continues to shrink the important factors. On the one hand, weak demand in overseas markets, overseas buyers are no longer as before, a large number of Yahuo, but decided to purchase according to the amount of volume. On the other hand, China's domestic vitamin market in pork, eggs and other agricultural products in the context of falling prices, farmers invest in a drop in demand, resulting in decline in the amount of feed-grade vitamin. At present, China's vitamin bulk raw material drug companies are trying to spend the winter, in addition to their own transformation, as the "five families" such as vitamin advantage of national pharmaceutical companies are all looking forward to the development of industry standards promulgated normative documents. Source:http://www.cospcn.com